Antibiotic Treatment for Urinary Tract Infections

Introduction to Treatment Guidelines

The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) suggests against using cefepime for third-generation cephalosporin-resistant Enterobacterales (3GCephRE) infections with a conditional recommendation based on very low certainty evidence 1
Studies show variable results depending on resistance mechanisms, with higher mortality sometimes reported with cefepime for ESBL infections, and higher mortality has been observed with cefepime when minimum inhibitory concentrations (MICs) are elevated, even within the susceptible dose-dependent category 1

For severe UTIs or bacteremia, carbapenems (imipenem or meropenem) are strongly recommended with moderate certainty evidence 1
For non-severe UTIs, piperacillin-tazobactam, amoxicillin-clavulanic acid, or quinolones (if susceptible) are conditionally recommended 1
Aminoglycosides (for short durations) or IV fosfomycin are recommended for complicated UTI without septic shock 1
Ertapenem is an alternative for non-septic shock 1
Meropenem 1g three times daily is a treatment option for UTIs caused by ESBL-producing E. coli, as suggested by the European Urology guidelines 2
Fosfomycin trometamol 3g single oral dose is an option for uncomplicated lower UTI, according to the Praxis Medical Insights guidelines 3
Cotrimoxazole is recommended as a good practice statement for non-severe complicated UTI 1

Ignoring MIC values can lead to inferior clinical outcomes, as elevated MICs within the susceptible range correlate with worse outcomes 1
Step-down therapy should be considered once patients are stabilized, with a switch to oral agents based on susceptibility testing 1
Always obtain urine culture before starting treatment and adjust therapy based on susceptibility results, as recommended by the European Urology guidelines 2
Reserve carbapenems and use targeted therapy based on susceptibility testing, as recommended by the Clinical Microbiology and Infection guidelines 1
In patients with heart failure risk, IV fosfomycin should be avoided due to increased risk of heart failure, as recommended by the Clinical Microbiology and Infection guidelines 1
For patients with renal impairment, adjust dosing of aminoglycosides and monitor renal function, as suggested by the European Urology guidelines 2

The European Urology guidelines recommend treatment duration of 5-7 days for uncomplicated UTI, 7-14 days for complicated UTI, and 14 days for men when prostatitis cannot be excluded 2
Consider shorter duration (7 days) when patient is hemodynamically stable and afebrile for at least 48 hours, as suggested by the European Urology guidelines 2

Carbapenems should be reserved when possible to prevent further resistance development 1
Beta-lactam/beta-lactamase inhibitor combinations (BLBLIs) have moderate-certainty evidence supporting their use, as recommended by the Clinical Microbiology and Infection guidelines 1
Aminoglycosides are conditionally recommended for short-duration therapy (<7 days) with moderate certainty, as the risk of nephrotoxicity increases after 7 days 1, 2
Intravenous fosfomycin is strongly recommended with high certainty evidence, but caution is advised due to an 8.6% risk of heart failure in patients with predisposing factors 1